ОбзорГрафикНовостиTraderScreen

BVT Discount Zert BIIB 31.12.2024/  DE000VD39RG4  /

Frankfurt Zert./VONT
08.11.2024  16:54:38 Изменение+0.620 Бид17:58:15 Предложение17:58:15 Базовый актив Цена исполнения Дата истечения Тип опциона
152.980EUR +0.41% 153.200
Величина цены спроса: 4,000		 153.370
Величина цены предложения: 4,000		 Biogen Inc - USD 31.12.2024 Call
TeleTrader 30.10 US opens lower after earnings, jobs, GDP data
TeleTrader 30.10 Biogen's Q3 revenue down 3% to $2.5 billion
Newsfile Corp 10.10 SAGE INVESTOR ALERT: Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to L...
GlobeNewswire 01.09 SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Invest...
GlobeNewswire 29.08 SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investo...
GlobeNewswire 26.08 Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encoura...
GlobeNewswire 26.08 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire 22.08 Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...
GlobeNewswire 19.08 Tiziana Life Sciences Appoints New Chief Executive Officer
GlobeNewswire 19.08 Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...
GlobeNewswire 15.08 Soleno Therapeutics Announces Updates to its Board of Directors
GlobeNewswire 15.08 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire 08.08 Royalty Pharma Reports Second Quarter 2024 Results
GlobeNewswire 01.08 C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
TeleTrader 01.08 Biogen books $2.5 billion in Q2 revenue
GlobeNewswire 01.08 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 31.07 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire 30.07 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire 30.07 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...
GlobeNewswire 30.07 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire 26.07 CVS Health Corporation Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law...
GlobeNewswire 26.07 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire 26.07 BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockh...
GlobeNewswire 22.07 Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Fir...
GlobeNewswire 22.07 DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of...